Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    82
    ...
ATC Name B/G Ingredients Dosage Form Price
J01AA08 VULGA XR G Minocycline - 105mg 105mg Tablet, film coated 1,983,512 L.L
J01DH02 MEROPENEM PANPHARMA G Meropenem (trihydrate) - 1g 1g Injectable powder for solution 7,278,513 L.L
J05AB01 CYCLOVEX G Aciclovir - 400mg 400mg Tablet, scored 2,687,685 L.L
L01CD01 PACLITAXEL MYLAN PHARMA 6MG/ML G Paclitaxel - 30mg/5ml 30mg/5ml Injectable concentrated powder for solution 5,923,692 L.L
L04AD02 TACROGRAF 0.5 G Tacrolimus - 0.5mg 0.5mg Capsule 7,004,024 L.L
M03AC11 SISACURE G Cisatracurium (besylate) - 20mg/10ml 20mg/10ml Injectable solution 1,408,347 L.L
S01AE07 IMOX G Moxifloxacin (HCl) - 0.5% 0.5% Drops 464,970 L.L
A02BC01 GASTRISEC G Omeprazole - 20mg 20mg Capsule 413,903 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 1mg 1mg Tablet, film coated 2,015,764 L.L
B01AF01 XAVIRAN G Rivaroxaban - 15mg 15mg Tablet, film coated 952,208 L.L
B05BC01 MANNITOL 20% INJECTION USP G Mannitol - 20% 20% Injectable solution 374,633 L.L
C01DX16 NICORANDIL BIOGARAN G Nicorandil - 10mg 10mg Tablet, scored 431,373 L.L
C10AA03 APO-PRAVASTATIN G Pravastatin Sodium - 20mg 20mg Tablet 775,397 L.L
J01AA08 VULGA XR G Minocycline - 80mg 80mg Tablet, film coated 1,983,512 L.L
J01DH02 MEROPENEM/ ANFARM G Meropenem (trihydrate) - 1g 1g Injectable powder for solution 6,443,725 L.L
J05AB01 VICLORIX 400 G Aciclovir - 400mg 400mg Tablet 3,589,851 L.L
L01CD01 PACLITAXEL NEAPOLIS G Paclitaxel - 30mg 30mg Injectable concentrate for solution 3,514,148 L.L
R03BA02 BUDESONIDE ARROW G Budesonide - 1mg/2ml 1mg/2ml Inhalation suspension for nebuliser 1,342,499 L.L
S01AE07 MOXITEC G Moxifloxacin (HCl) - 5mg/ml 5mg/ml Drops solution 464,970 L.L
A02BC01 HYPOSEC G Omeprazole - 20mg 20mg Capsule 659,827 L.L
A07AA02 MEDISTAN G Nystatin - 500,000IU 500,000IU Capsule 417,231 L.L
A10BG03 PIODIAB 15 G Pioglitazone HCl - 15mg 15mg Tablet 1,053,317 L.L
B01AF01 ZARLAN G Rivaroxaban - 15mg 15mg Tablet, film coated 2,015,764 L.L
B05BC01 MANNITOL 20% INJECTION USP G Mannitol - 20% 20% Injectable solution 613,662 L.L
C01DX16 NICORANDIL BIOGARAN G Nicorandil - 20mg 20mg Tablet 822,432 L.L
C09AA05 ACURIL G Ramipril - 2.5mg 2.5mg Tablet 497,222 L.L
C10AA03 PRAVASTATINE ARROW G Pravastatin - 20mg 20mg Tablet, breakable 526,786 L.L
D06BX01 CUTIDERMINE G Metronidazole - 1% 1% Gel 593,850 L.L
J01AA08 VULGA XR G Minocycline - 55mg 55mg Tablet, film coated 1,983,512 L.L
J01DH02 MEROZAN G Meropenem - 1g 1g Injectable powder for solution 6,443,725 L.L
    ...
    82
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026